Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

Think3.headache.jpg

Rheum Views on the Upside and Downside of COVID-19

The world has been turned upside down in the last 6 weeks. Medicine and rheumatology have certainly changed – a frightening experience for Chicken Little, a disaster for the pessimist, a challenge for the pragmatist and an opportunity for the optimists amongst us. Last week I asked our audience to tell me their “upside or downside of COVID-19”. Read on to see how your peers have operating or thinking.

Read Article
Kawasaki.jpg

Rare Inflammatory Syndrome in Kids with COVID-19

Pediatricians are asking the question - could this be a rare manifestation of COVID-19 in children?

Read Article
COVID19.needles.Rx_.jpg

IL-6 Inhibitors May Benefit COVID-19 Infection

In the last few days there have been encouraging "preliminary" reports that IL-6 inhibition by either tocilizumab or sarilumab may be efficacious in patients with severe coronavirus infections.

Read Article
RA.vascular.cholesterol.plaque.jpg

TNF Inhibitors Reduce and Stabilize Coronary Plaque

Arthritis & Rheumatology reports that biologic (bDMARD) use in rheumatoid arthritis may decrease cardiovascular disease risk by retarding coronary plaque formation and progression (especially non‐calcified and low‐attenuation plaque).

Read Article
Chloroquine.jpg

High Dose Chloroquine Harmful in Severe COVID-19

JAMA Open Network reports an interim analysis of the Brazilian CloroCovid-19 trial showing thta higher doses of chloroquine (CQ) in the treatment of severe COVID-19 was associated with QTc interval prolongation and increased mortality.

Read Article
podcastLogo-01%20RESIZED.jpg

RheumNow Podcast – In Times of Trouble (4.24.20)

Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com

Read Article
think.know_.guess_.jpg

How Has COVID-19 Affected You?

I need your HELP and INPUT.

Read Article
COVID.virus_.corona.jpg (keep)

Potential Role of B Cells in COVID

A pre-proof letter to the editor in the Journal of Allergy and Clinical Immunology presents a series of patients with immunoglobulin deficiency disorders and how they differentially responded when infected with the coronavirus. They identified seven Primary Antibody Deficiencies patients with COVID-19 infection; five affected with Common Variable Immune Deficiencies and two affected with Agammaglobulinemia, one with X-linked Agammaglobulinemia and one with Autosomal Recessive Agammaglobulinemia.

Read Article
CBD.cannabis.oil_.jpg

FDA Consumer Warnings on Cannabis and CBD

The FDA issued a new consumer update on what you need to know about Cannabis or Cannabis-derived Compounds, Including CBD. This is part of the FDA effort to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.

Read Article
guidelines.jpg (keep)

NIH Consensus Guidelines for the Treatment of COVID-19

A National Institutes of Health (NIH) expert panel has developed consensus treatment guidelines for the management of coronavirus (COVID-19). To date no drug has been proven to be safe and effective for treating COVID-19. Moreover, they found no evidence to recommended the use of hydroxychloroquine for prophylaxis or treatment of COVID-19 outside of a current clinical trial.

Read Article
×